The global PD1 resistant head & neck cancer market is predicted to be worth US$ 1.54 billion in 2023 and US$ 5 billion by 2033, with a CAGR of 12.5%. The growing geriatric population, as well as the increasing number of initiatives by government and non-governmental organisations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer (SPOHNC), are creating a highly favourable environment for the global PD1 resistant head and neck cancer market to grow.
Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16237
Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to traditional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body’s natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, for instance, are occasionally seen in and surrounding tumors. An estimated 75% of head and neck cancers are caused by alcohol and cigarette intake.
However, frequent treatment of cancer of the head and neck involve a mix of radiation and chemotherapy treatment, which results into various adverse effects like hair loss, speech impairment, and loss of natural voice. Additionally, after undergoing cancer surgery, people have difficulty eating. Thus, these factors will restrain market growth.
Key Takeaways
- North America is expected to dominate the Head and Neck cancer market with a CAGR of 11.1% during the forecast period.
- APAC is projected to grow with a fastest CAGR of 11.5% during the forecast period.
- PDL1 Inhibitors is anticipated to lead the market by product type.
- Advancements in biochemistry and Genomics like Immunotherapy will lead to market expansion.
- North America is projected to dominate PDL1 segment market by 2033.
- In APAC, China will dominate the market with market value of USD 250 Million in 2023.
“With rapid advancements in oncology, healthcare practitioners are discovering novel approaches to diagnose and treat the most debilitating cancers, including PD1 resistant HNC. This is paving way for various avenues for developing treatment approaches,” remarks an FMI analyst.
Talk to Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16237
Competitive Landscape
Key players in the Head and Neck Cancer market are: Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.
- In February 2020, Galera Therapeutics, Inc., announced that Avasopasem manganese (GC4419), a novel drug molecule is in their pipeline. Avasopasem manganese (GC4419), the candidate drug molecule is being developed for reducing the severe oral mucositis (SOD) which is normally induced due to radiotherapy. Avasopasem manganese (GC4419) selectively and rapidly convert superoxide into hydrogen peroxide and oxygen, which in turn protect the normal tissues from the ill-effects of superoxide. If the condition is left untreated, the superoxide can attack and damage the non-cancerous tissue, leading to many side-effects, which can limit the efficiency of radiotherapy in the patients.
- In July 2022, Bristol Myers Squibb received positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending approval for LAG-3-blocking antibody combination Opdualag (nivolumab and relatlimab) for the treatment of patients with unresectable or metastatic melanoma.
- In October 2021, Merck received the United States Food and Drug Administration (FDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test.
Key Segments Profiled in the PD1 Resistant Head and Neck Cancer Market Industry Survey
PD1 Resistant Head and Neck Cancer Market by Product:
Cytotoxic Agents
- Antimetabolites
- Antitubulins
- Others – Platinum Agents, Fluoropyrimidines
EGFR Inhibitors
- Erbitux
- Vectibix
- Theracim/Theraloc
EGFR Inhibitors
- Tarceva
- Tykerb/Tyverb
PD1 Inhibitors
- Keytruda
- Opdivo
Pipeline Drugs
- EGFR Inhibitors
- PDL1 Inhibitors
- CTLA4 Inhibitors
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16237
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs